New developments in the management of diffuse large B-cell lymphoma

Hematology

Volumn 17, Issue SUPPL. 1, 2012, Pages

  Habermann, Thomas M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Diffuse large B cell lymphoma; Lenalidomide; R CHOP; Whole genome sequencing

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; EPRATUZUMAB; ETOPOSIDE; EVEROLIMUS; IFOSFAMIDE; LENALIDOMIDE; PREDNISONE; RITUXIMAB; SORAFENIB; TIPIFARNIB; TOSITUMOMAB; VINCRISTINE; VINDESINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; WHOLE BODY RADIATION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; PREDNISONE; RECURRENCE; STEM CELL TRANSPLANTATION; THALIDOMIDE; VINCRISTINE; VINDESINE;

EID: 84859749572     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1179/102453312X13336169156014     Document Type: Review

References (45)

1. Percy C, O'Conor G, Reis LG, Jaffe ES. Non-Hodgkin's lymphomas: application of the International Classification of Disease for Oncology (ICD-O) to the working formulation. Cancer. 1984;54:1435-8.
2. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
3. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235-42.
4. Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the RCHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomas de l'Adulte. J Clin Oncol. 2005;23:4117-26.
5. Coffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:2040-5.
6. Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-7.
7. Pfreudschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized study of the MabThera International Trial (MinT) Group. Lancet Oncol. 2006;7:379-91.
8. Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al. Randomized intergroup trial of first line treatment for young low-risk patients (,61 years) with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-6-year follow-up of the Mint study of the Mabthera International Trial (Mint) Group. Blood. 2010;116:55a.
9. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027-33.
10. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105-16.
11. Pfreunshuh M, Ziepert M, Reiser M, Poeschel V, Wilhelm S, Gaska T, et al. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group for elderly in diffuse large B-cell lymphoma. Blood. 2008;112:219a.
12. Halaas JH, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, et al. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma. 2005;46:541-7.
13. Brusamolio E, Rusinoi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al. Dose-dense R-CHOP-14 supported by pegfilgrastrim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496-502.
14. Delarue R, Tilly H, Salles G, Gisselbrecht C, Mounier N, Fournier M, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the LNH03-6B study. Blood. 2009;114:169a.
15. Cunningham D, Smith P, Mouncey W, Qian W, Jack AS, Pocock C, et al. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2011;29:504s.
16. Schmitz N, Nickelsen M, Ziepert M, Haenel P, Borchmann C, Schmidt A, et al. Aggressive chemotherapy (CHOEP-14) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Lymphoma Study Group (DSHNHL). Blood. 2009;114:168a.
17. Recher C, Coffier B, Haioun C, Mounier N, Emile JF, Ranta D, et al. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs. standard R-CHOP in younger patients with diffuse large B-cell lymphoma: Groupe d'Etude Des Lymphomes De l'Adulte (GELA) study LNH03-2B. Blood. 2010;116:53-4a.
18. Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-8.
19. Applebaum FR. Hematologic cell transplantation for non-Hodgkin lymphoma: yesterday, today, and tomorrow. J Clin Oncol. 2008:26:2927-9.
20. McCarthy PL, Hahn T, Hassebroek A, Klein JP, Rizzo JD, Parsons S, et al. Significant improvement in overall survival in patients who underwent autologous hematopoietic cell transplant in the US and Canada between 1994 and 2005. Blood. 2010;116:990a.
21. Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90.
22. Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079-87.
23. Krishan A, Palmer J, Nademanee A, Tsai NC, Simpson JR, Nademanee A, et al. Comparative analysis of autologous hematopoietic cell transplantation with radioimmuntherapy (RIT) based conditioning versus total body irradiation (TBI) for high-risk diffuse large B-cell lymphoma (DLBCL): toxicity and efficacy. Blood. 2010;116:18a.
24. Hitz F, Moccia JM, Gasgoyne RD, Hoskins P, Moccia AA, Savage KJ, et al. Outcome of patients with chemotherapy refractory and early progressive diffuse large B-cell lymphoma after R-CHOP. Blood. 2010;116:731a.
25. Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, et al. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP±R for eight cycles to CHOP±R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29:504s.
26. Micallef IN, Kahl BS, Maurer MJ, Gayko U, Cesano A, Ansell SM, et al. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006;107:2826-32.
27. Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al. Epratuzumab with rituxiab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118:4053-61.
28. Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center markers. J Clin Oncol. 2008;26:2717-24.
29. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069-76.
30. Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544-52.
31. Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol. 2008;26:4952-7.
32. Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol. 2011;22:1622-77.
33. Nowakowski GS, Laplant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, et al. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25:1977-81.
34. Freidberg JW, Unger JM, Burack RB, W. Gopal AK, LeBlanc ML, Ajay K, et al. R-CHOP with Iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group Protocol S0433. Blood. 2010;116:260a.
35. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741-6.
36. Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, et al. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;118:4882-9.
37. Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341-7.
38. Kumar S, Porrata LF, Ansell SM, Colgan JP, LaPlant B, Gertz MA, et al. Phase I trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. Blood;116:1155a.
39. Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamainib disodium has significant clinical activity in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578-85.
40. Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95:135-43.
41. Cartron G, Thieblemont C, Solal-Celegny P, Morshchhauser F, Haloun C, Bouabdallah R, et al. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients-first results from a phase II study in relapsed/refractory DLBCL and MCL. Blood. 2010;116:1185a.
42. Coiffier B, Bosly A, Wu KL, Verhoef G, Koen VE, Martinelli G, et al. Ofatumomab montherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a phase multicenter II study. Blood. 2010;116:1613a.
43. Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active inpatients with indolent non-Hodgkin's lymphoma. Haematologica. 2011;96:567-73.
44. Fowler N, Sharman JP, Smith SM, Boyd T, Grant B, Kolibaba KS, et al. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/ refractory B-cell malignancies: results from a phase I trial. Blood. 2010;116:425a
45. Lohr J, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. PNAS. 2012. February, [Epub ahead of print]; doi/10.1073/pnas.1121343109.